Evaluation of the Safety and Efficacy of NeuroEPO in Subjects With Mild to Moderate Alzheimer's Disease

The goal of this clinical trial is to test if NeuroEPO improves or maintains cognition in adults with mild to moderate Alzheimer's Disease using a cannula attached to a syringe for delivery. It will also learn the safety of NeuroEPO. The main questions it aims to answer are: Does NeuroEPO lower or maintain a person's cognition who has been diagnosed with Alzheimer's Disease? What medical problems do participants have when taking NeuroEPO? Researchers will compare NeuroEPO to a placebo (a look-alike substance that contains no drug) to see if NeuroEPO works to treat Alzheimer's Disease. Participants will: Take NeuroEPO or a placebo three times a week for one year Visit the clinic to determine eligibility, for cognitive testing and blood tests at the start and end of the trial and at 1, 2, 6 and 12 months for check ups and blood collection

NCT Number	NCT07178678
Lead Sponsor	University of Saskatchewan Collaborators: Center of Molecular Immunology, Cuba
Conditions	Mild Alzheimer's Disease, Moderate Alzheimer's Disease
Enrollment	90 participants
Start Date	2025-11
Primary Completion	2030-03 (estimated)
Study Completion	2030-12 (estimated)
Updated on ClinicalTrials.gov	2025-09-17